- Disease severity and history of atopic keratoconjunctivitis (AKC) are associated with risk for dupilumab-induced ocular surface disease (DIOSD) in patients with atopic dermatitis.
Why this matters
- Study provides further evidence that DIOSD is a common adverse event, and identifies risk factors.
- 43.2% of patients had new or exacerbated symptoms of ocular surface disease after treatment.
- 19% of these experienced transient dry eye sensation.
- 56% of these experienced chronic dry eye sensation.
- 25% of these experienced marked blepharoconjunctivitis.
- 75% of patients with DIOSD had severe atopic dermatitis (Investigator’s Global Assessment score of 5) compared with 17.6% of patients without DIOSD (P=.001).
- Prior AKC was associated with increased DIOSD risk (OR, 23.28; P=.005), whereas family history of atopy was associated with decreased DIOSD risk (OR, 0.13; P=.05).
- Periocular 0.03% or 0.1% tacrolimus ointment was associated with resolution of signs and symptoms in all patients with blepharoconjunctivitis.
- 37 patients with atopic dermatitis treated with dupilumab were included.
- Funding: None disclosed.
- Retrospective study.
- Small patient sample size.